Trading / Browse Companies / Epic Sciences stock

Epic Sciences Stock

epicsciences.comBioTechFounded: 2008Funding to Date: $161MM

Epic Sciences is a developer of novel diagnostics designed to personalize and advance the treatment and management of cancer.

Buy or sell Epic Sciences stock
Register for Details

For more details on financing and valuation for Epic Sciences, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

OverviewFinancingsValuation

Team

Management Team

Murali Prahalad Ph.D
Chief Executive Officer & President
Pascal Bamford Ph.D
Chief Scientific Officer and Head of Laboratory Operations
Ian Miller JD
Chief Business Officer and General Counsel
Ryan Dittamore
Chief of Medical Innovation and Head of Translational Research Partnerships
Dave Henderson
Chief Information Officer
Dena Marrinucci Ph.D
Co-Founder & Member Clinical Advisory Board

Board Members

Andrew ElBardissi MD
Deerfield Management
Evgeny Zaytsev Ph.D
RusnanoMedInvest
Gregory Critchfield MD
Gregory Lucier
John Sage
Kim Kamdar Ph.D
Domain Associates
Peter Kuhn Ph.D
Simon Greenwood Ph.D
Roche Venture Fund

Other companies like Epic Sciences in the BioTech sector

Mammoth Biosciences
Sector
BioTech
Last Round Est. Valuation
$1.08B
Ginkgo Bioworks
Sector
BioTech
Last Round Est. Valuation
$4.89B
PROCEPT BioRobotics
Sector
BioTech
Last Round Est. Valuation
$872.62MM
Synthego
Sector
BioTech
Last Round Est. Valuation
$486.63MM
eFFECTOR Therapeutics
Sector
BioTech
Last Round Est. Valuation
$186.12MM
Human Longevity
Sector
BioTech
Last Round Est. Valuation
$50.4MM
Grail
Sector
BioTech
Last Round Est. Valuation
$4.26B
Arsenal Biosciences
Sector
BioTech
Last Round Est. Valuation
$185MM
Caris Life Sciences
Sector
BioTech
 
 

News

FinSMEs 09/12/2018
Epic Sciences Closes $52M in Series E Financing | FinSMEs
Epic Sciences, a San Diego, CA-based developer of blood tests that predict therapeutic benefit for cancer patients, completed a $52m Series E financing

Trending Companies

Frequently Asked Questions